Tumors are not the passive lumps we used to think they were. They actively recruit nerves, hijack neural signaling, and use your nervous system's own communication channels to fuel their growth and spread. A review in Military Medical Research compiles the evidence and suggests something that sounds a bit strange at first: why not repurpose psychiatric medications as cancer treatments?
Tumors Have Learned to Make Phone Calls
The relationship between tumors and nerves is a two-way street, and it's not a friendly neighborhood. Nerves infiltrate the tumor microenvironment and release neurotransmitters and growth factors that tumors absolutely love. This signaling cocktail provides exactly what cancer cells crave: signals to proliferate, ways to evade the immune system, instructions for building new blood vessels, and cues for metastasis.
Scientists have tried literally cutting the phone lines. Denervation means surgically removing or disabling the nerves around a tumor, and in some contexts it slows cancer growth. If the tumor depends on neural input, take away the neural input and the tumor should suffer.
But of course, biology refuses to be simple. The outcomes vary dramatically depending on which type of nerves you're talking about and which type of tumor. Sympathetic nerves versus parasympathetic nerves. Different cancer types. Different body locations. Some denervation helps. Some doesn't. Some might even make things worse. The relationship is real but complicated.
Raiding the Pharmacy for Old Drugs
Here's where things get interesting from a practical standpoint. If tumors are exploiting neural signaling pathways, what about drugs that already exist to modulate those same pathways? We've got decades of psychiatric and cardiovascular medications that tweak neurotransmitter systems. Maybe some of them could pull double duty.
The review highlights several candidates.
Beta-blockers are the workhorses of blood pressure and anxiety management. They block adrenergic receptors, the same receptors that respond to stress hormones like adrenaline. Tumors often exploit these stress hormone signals to their advantage. Some observational studies have found that cancer patients who were already taking beta-blockers for other reasons seemed to fare better than expected. Correlation isn't causation, but it's suggestive.
Antipsychotics and antidepressants modulate dopamine and serotonin signaling. It turns out tumors may be eavesdropping on these pathways too. Laboratory studies have shown that some of these drugs have anti-cancer effects in cell cultures and animal models. They weren't designed to fight cancer, but they might do it anyway.
The appeal here is practical. These are drugs with decades of safety data. We know their side effects, their dosing, their interactions. If any of them turn out to have genuine anti-cancer activity, they could be moved toward cancer treatment much faster than a brand new drug developed from scratch.
Sending the Medicine Straight to the Tumor
One challenge with repurposing psychiatric drugs for cancer is that the doses needed to affect a tumor might be higher than what's safe for systemic use. You don't want to give someone so much antidepressant that they have side effects everywhere just to get enough of it to the tumor.
Enter nanotechnology. The review discusses approaches for delivering neural-modulating drugs directly to tumors using nanoparticle carriers. The idea is to concentrate the firepower where it matters while sparing the rest of the body. Maximum tumor effect, minimum systemic side effects.
This is still largely experimental, but it represents a path forward for drugs that might work great on tumors but cause problems when they're circulating throughout the entire body.
A New Therapeutic Angle
The case for neural-targeted cancer therapy has several selling points. First, the drugs already exist and have extensive safety records. Second, they might work through mechanisms that are completely different from existing cancer treatments, which means they could overcome resistance to chemotherapy or radiation. Third, neural signaling affects the immune system, so targeting it might enhance the effectiveness of immunotherapy.
Cancer neuroscience used to be an academic curiosity, an interesting observation without clear practical implications. Tumors recruit nerves? Huh, that's weird. Nerves help tumors grow? Strange, but so what?
Now it's becoming a translational research area with real therapeutic potential. The weird truth about nerve-tumor cooperation is turning into actual treatment strategies. Your nervous system has been unwittingly helping tumors for as long as cancer has existed. Maybe it's time to make it work for the other side.
Reference: Liu QQ, et al. (2025). Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies. Military Medical Research. doi: 10.1186/s40779-025-00661-9 | PMID: 41163091
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.